Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | BACE1 | P56817 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081533 | 0.82 | PARP1 (0.57) | ALDH1A1MAPTSMN1; SMN2LMNATDP1 | |
| SCHEMBL5493423 | 0.81 | DRD3 (0.55) | — | |
| SCHEMBL5498350 | 0.80 | DRD4 (0.46) | MAPT | |
| SCHEMBL5493145 | 0.80 | HDAC1 (0.46) | MAPT | |
| SCHEMBL4513293 | 0.80 | MAPK1 (0.41) | ALDH1A1LMNAPOLBKMT2AL3MBTL1 | |
| SCHEMBL2718838 | 0.80 | DRD3 (0.42) | MAPTPOLBMEN1KMT2A | |
| SCHEMBL10511598 | 0.78 | DRD3 (0.46) | MAPT | |
| SCHEMBL18111982 | 0.75 | LMNA (0.39) | ALDH1A1MAPTSMN1; SMN2LMNAACHE | |
| SCHEMBL16371471 | 0.75 | LMNA (0.39) | ALDH1A1MAPTSMN1; SMN2LMNAACHE | |
| SCHEMBL9145657 | 0.74 | SIRT6 (0.46) | ALDH1A1MAPTLMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757608-A1 | New benzazepine derivatives, medicaments containing the same and their use in the preparation of medicaments | Sanochemia Pharmazeutika Aktiengesellschaft (AT) | 2007-02-28 | — | — | EP | disclosed |
| US-7101890-B2 | Benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2006-09-05 | — | — | US | disclosed |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2004-04-08 | — | — | US | disclosed |
| US-6638925-B2 | In particular benzofuro(3a,3,2,ef)(2)benzazepin; treatment of Alzheimer's disease and related dementia conditions, Langdon-Down syndrome | SANOCHEMIA LTD. (MT) | 2003-10-28 | — | — | US | disclosed |
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | SANOCHEMIA LTD. (MT) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | PSEN2, BACE2, BACE1 | MCHR1 4671/4885ALDH1A1 2241/4885MAPT 235/4885 |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | BACE2, PSEN2, BACE1 | MCHR1 4609/4885ALDH1A1 1803/4885MAPT 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.